

A-Engrossed House Bill 3380

Ordered by the House April 10
Including House Amendments dated April 10

Sponsored by Representative TRAN; Representatives HUDSON, NELSON, PHAM H, Senators GORSEK, JAMA, MEEK, WOODS

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure.

[Allows physician to prescribe continuous glucose monitor to certain patients whether or not physician specializes in endocrinology. Requires medical assistance and health insurance to provide, as pharmacy benefit, coverage of or payment or reimbursement for continuous glucose monitor prescribed by physician.] **Requires medical assistance to include continuous glucose monitor for specified recipients of medical assistance. Defines "continuous glucose monitor."**

A BILL FOR AN ACT

1
2 Relating to continuous glucose monitors.

3 **Be It Enacted by the People of the State of Oregon:**

4 **SECTION 1. Section 2 of this 2023 Act is added to and made a part of ORS chapter 414.**

5 **SECTION 2. (1) As used in this section, "continuous glucose monitor" means:**

6 (a) **An instrument or device that is designed and offered for the purpose of measuring**
7 **glucose levels at set intervals by means of a small electrode placed under the skin and held**
8 **in place by an adhesive; and**

9 (b) **Any repair or replacement parts for the instrument or device.**

10 (2) **Notwithstanding ORS 414.065 and 414.690, medical assistance shall include a contin-**
11 **uous glucose monitor prescribed for a recipient of medical assistance if the recipient:**

12 (a)(A) **Is diagnosed with any type of diabetes that requires the use of insulin more than**
13 **twice per day;**

14 (B) **Has evidence of level two or three hypoglycemia; or**

15 (C) **Is diagnosed with glycogen storage disease type 1a; and**

16 (b) **At least once every six months attends a visit with a health care provider in order**
17 **to assess the benefits of the recipient's use of the continuous glucose monitor.**

18 **SECTION 3. Section 2 of this 2023 Act applies to prescriptions issued on or after the ef-**
19 **fective date of this 2023 Act.**

20

NOTE: Matter in **boldfaced** type in an amended section is new; matter *[italic and bracketed]* is existing law to be omitted. New sections are in **boldfaced** type.